Form 4: Madrigal Pharmaceuticals Director Richard Levy Receives Equity Compensation

Madrigal Pharmaceuticals, Inc. Director Richard S. Levy was granted 715 restricted stock units and options to purchase 1,290 shares of common stock, vesting in 2026 subject to continued service.

Summary

• Richard S. Levy, a Director of Madrigal Pharmaceuticals, Inc. (MDGL), was granted equity awards on June 20, 2025.
• The grant includes 715 restricted stock units (RSUs) and stock options to acquire 1,290 shares of common stock.
• The RSUs and stock options are scheduled to vest 100% on the date of the Issuer's annual meeting of stockholders in 2026.
• Vesting is contingent upon Mr. Levy's continued service as a director of Madrigal Pharmaceuticals until the vesting date.
• The stock options have an exercise price of $285.73 per share and an expiration date of June 20, 2035.
• Following these transactions, Mr. Levy beneficially owns 21,197 shares of common stock and 1,290 stock options.

Sentiment

Score: 7

Explanation: The filing indicates a standard equity grant to a director, aligning interests and suggesting continued board stability, which is generally positive for corporate governance. There are no negative implications or significant new risks.

Positives

• The grant of equity awards aligns the director's interests with those of shareholders, incentivizing long-term performance.
• Continued service of a director like Richard S. Levy, who is receiving these grants, suggests stability in corporate governance.

Risks

• The vesting of the equity awards is contingent on the reporting person's continued service, meaning the awards could be forfeited if service ceases before the 2026 annual meeting.
• The value of the stock options is subject to the future market price of Madrigal Pharmaceuticals' common stock, posing a market risk.

Future Outlook

The granted restricted stock units and stock options are forward-looking, with vesting contingent upon Richard S. Levy's continued service as a director until the Issuer's annual meeting of stockholders in 2026. The stock options have a long-term expiration date of June 20, 2035, indicating a long-term incentive.

Management Comments

• Represents a grant of restricted stock units, which vest on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided the Reporting Person continues in service with the Issuer on such date.
• The option vests as to 100% of underlying shares on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided that the Reporting Person continues to serve as a director of the Issuer until such date.

Industry Context

This Form 4 filing details a routine equity grant to a director, a common practice in publicly traded companies, particularly in the pharmaceutical sector like Madrigal Pharmaceuticals. Such grants are designed to align the interests of directors with those of shareholders and incentivize long-term commitment and performance.

Comparison to Industry Standards

• Equity grants to directors, comprising a mix of restricted stock units and stock options, are a standard component of compensation packages across the pharmaceutical and biotechnology industries.
• The vesting schedule tied to continued service and future annual meetings is typical for long-term incentive plans aimed at retaining key board members.
• While specific comparable companies or projects are not detailed in this filing, the structure of this compensation aligns with general industry practices for non-employee directors in companies of similar size and stage within the biotech/pharma space.

Corporate Governance

Related Party Transactions

• The grant of equity awards to Richard S. Levy, a director of Madrigal Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of equity awards may result in minor dilution over time as shares vest and options are exercised, but it also serves to align the director's interests with shareholder value creation.

Next Steps

• Richard S. Levy's continued service as a director of Madrigal Pharmaceuticals until the 2026 annual meeting.
• Vesting of 715 restricted stock units and 1,290 stock options on the date of the Issuer's annual meeting of stockholders in 2026.
• Potential exercise of stock options by Richard S. Levy at an exercise price of $285.73 per share, anytime between vesting and the expiration date of June 20, 2035.

Key Dates

Keywords

Madrigal Pharmaceuticals, MDGL, Richard S. Levy, Form 4, SEC filing, insider transaction, equity grant, restricted stock units, stock options, director compensation, corporate governance